Though these parameters were not improved by SDP treatment in a pilot-scale clinical intervention [30], in the present study, the SDP supplementation to an AD significantly reversed the increase in the serum levels of the transaminases GPT and GOT, further reinforcing the importance of validating preclinical results with clinical studies. This evidence concerns the gene GPT and Alzheimer disease.